IQVIA艾昆纬：2025年扩大美国新兴生物制药的选择：变革的十年报告（英文版）

EBPs are defined as companies with estimated R&D spend below $200Mn or prescription sales up to $500Mn, including both pre–commercial and commercial entities. They represent a major segment of the biomedical innovation ecosystem, responsible for originating, developing, registering, and commercializing new drugs. In the past 10 years, EBPs accounted for 74% of all companies involved in clinical trials, initiated 50% of all industry–sponsored, interventional Phase I–III trials, originated